This week, the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), the nation’s medical research agency with over 27 institutes and centers across the USA, has launched a study which aims to find out whether different approved therapies or investigative drugs in late-stage clinical research are showing promising results against COVID-19. The goal of this study is to see, whether some results are eligible for larger clinical trials.
New ACTIV-5 Big Effect Trial
The new study is called ACTIV-5 Big Effect Trial and aims to find new pathways for urgently needed COVID-19 treatments. To do so, researchers are looking into repurposing either licensed or late-stage-development medicine to test them to identify the most promising agents for larger clinical studies. The trial is planning to enroll hospitalized adult volunteers with COVID-19 in over 40 US research sites and is being conducted in collaboration with the NIH’s public-private partnership ‘Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.
The clinical trial is a phase 2 adaptive, randomized, double-blinded, placebo-controlled study that compares a variety of different investigational therapies to a common control arm to test which one has the greeted effects. Therapies that will be tested include risankizumab, a monoclonal antibody developed by Boehringer Ingelheim, and AbbVie, in conjunction with the antiviral drug remdesivir, compared to placebo plus remdesivir.
Further, the trial will also research the investigational monoclonal antibody lenzilumab, developed by Humanigen, with remdesivir, compared to a placebo and remdesivir. So far, remdesivir has shown promising clinical effects on patients with severe COVID-19 symptoms that require supplemental oxygen. According to NIAID Director Anthony S Fauci, M.D., the goal of the study is to identify the experimental therapeutics that show the most clinical promise as COVID-19 treatment and move them into large-scale testing, and eliminating the ones that are not working.
Partner with accredited companies
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Still a little unsure? Check out what our customers have to say about us here.